Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06BUA
|
||||
| Former ID |
DIB002912
|
||||
| Drug Name |
Nexopamil
|
||||
| Synonyms |
LU-49938
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Phase 2 | [1] | ||
| Company |
BASF AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H40N2O3
|
||||
| Canonical SMILES |
c1([C@@](C#N)(C(C)C)CCCN(CCCCCC)C)cc(c(c(c1)OC)OC)OC
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Calcium channel | Target Info | Blocker | [1] | |
| 5-HT 2 receptor | Target Info | Modulator | [1] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| References | |||||
| REF 1 | Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.